Scienture Holdings, Inc. SCNX

What this company does

Scienture LLC is a specialty pharmaceutical company focused on the commercialization and development of products for the treatment of cardiovascular (“CVS”) and Central Nervous System (“CNS”) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Scienture LLC obtained regulatory approval of its first product candidate, SCN-102 (ArbliTM) in the first quarter of 2025. Scienture, LLC completed the acquisition of the commercial ready product asset REZENOPYTM in the first quarter of 2025. ArbliTM (SCN-102) is an oral liquid formulation of losartan potassium in development under the 505(b)(2) pathway, for (i) treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old, (ii) reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy, and (iii) treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ArbliTM (SCN-102) is the first and only FDA approved oral liquid formulation of losartan on the market. On March 13, 2025, the FDA approved the SCN-102 NDA to be launched as ARBLITM (losartan potassium) Oral Suspension, 10mg/mL. Scienture LLC commercially launched the product in the third quarter of 2025.

Written from the business description in Scienture Holdings, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 30 March 2026. Every sentence was checked against that document before publication.